NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
Lumos Pharma
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)